Evaxion Biotech Statistics

Total Valuation

Evaxion Biotech has a market cap or net worth of $11.50 million. The enterprise value is $6.45 million.

Market Cap	11.50M
Enterprise Value	6.45M

Important Dates

The next estimated earnings date is Tuesday, May 27, 2025, before market open.

Earnings Date	May 27, 2025
Ex-Dividend Date	n/a

Share Statistics

Evaxion Biotech has 6.27 million shares outstanding. The number of shares has increased by 78.19% in one year.

Current Share Class	n/a
Shares Outstanding	6.27M
Shares Change (YoY)	+78.19%
Shares Change (QoQ)	+6.98%
Owned by Insiders (%)	6.92%
Owned by Institutions (%)	4.15%
Float	4.62M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.49
Forward PS	0.95
PB Ratio	26.28
P/TBV Ratio	149.04
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	1.96
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

Current Ratio	n/a
Quick Ratio	n/a
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-5.43

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-69.45%
Return on Invested Capital (ROIC)	-246.40%
Return on Capital Employed (ROCE)	n/a
Revenue Per Employee	$67,245
Profits Per Employee	-$233,898
Employee Count	49
Asset Turnover	0.24
Inventory Turnover	n/a

Taxes

Income Tax	-690,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -88.56% in the last 52 weeks. The beta is -0.24, so Evaxion Biotech's price volatility has been lower than the market average.

Beta (5Y)	-0.24
52-Week Price Change	-88.56%
50-Day Moving Average	2.47
200-Day Moving Average	9.66
Relative Strength Index (RSI)	39.80
Average Volume (20 Days)	67,012

Short Selling Information

Short Interest	22,395
Short Previous Month	86,685
Short % of Shares Out	1.32%
Short % of Float	n/a
Short Ratio (days to cover)	2.07

Income Statement

In the last 12 months, Evaxion Biotech had revenue of $3.30 million and -$11.46 million in losses. Loss per share was -$12.40.

Revenue	3.30M
Gross Profit	3.30M
Operating Income	-15.07M
Pretax Income	-22.92M
Net Income	-11.46M
EBITDA	-14.87M
EBIT	-15.07M
Loss Per Share	-$12.40

Full Income Statement

Balance Sheet

The company has $4.58 million in cash and n/a in debt, giving a net cash position of $4.58 million or $0.73 per share.

Cash & Cash Equivalents	4.58M
Total Debt	n/a
Net Cash	4.58M
Net Cash Per Share	$0.73
Equity (Book Value)	74,000
Book Value Per Share	0.07
Working Capital	4.58M

Full Balance Sheet

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-457.42%
Pretax Margin	-368.77%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Evaxion Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-78.19%
Shareholder Yield	n/a
Earnings Yield	-103.92%
FCF Yield	n/a

Analyst Forecast

The average price target for Evaxion Biotech is $33.33, which is 1,716.35% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$33.33
Price Target Difference	1,716.35%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	217.02%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on January 14, 2025. It was a reverse split with a ratio of 0.2:1.

Last Split Date	Jan 14, 2025
Split Type	Reverse
Split Ratio	0.2:1

Scores

Evaxion Biotech has an Altman Z-Score of -12.44. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-12.44
Piotroski F-Score	n/a